Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 528

1.

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS.

Clin Cancer Res. 2014 Jun 1;20(11):2898-909. doi: 10.1158/1078-0432.CCR-13-3052. Epub 2014 Apr 8.

2.

PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.

Nakae S, Sasaki H, Hayashi S, Hattori N, Kumon M, Nishiyama Y, Adachi K, Nagahisa S, Hayashi T, Inamasu J, Abe M, Hasegawa M, Hirose Y.

PLoS One. 2015 Nov 11;10(11):e0142750. doi: 10.1371/journal.pone.0142750. eCollection 2015.

3.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

4.

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D.

Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14.

5.

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA.

Oncotarget. 2013 Oct;4(10):1729-36.

6.

IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.

Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, Chan TA, Huse JT.

Clin Cancer Res. 2012 May 1;18(9):2490-501. doi: 10.1158/1078-0432.CCR-11-2977. Epub 2012 Mar 13.

7.

IGFBP2 expression predicts IDH-mutant glioma patient survival.

Huang LE, Cohen AL, Colman H, Jensen RL, Fults DW, Couldwell WT.

Oncotarget. 2017 Jan 3;8(1):191-202. doi: 10.18632/oncotarget.13329.

8.

IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.

Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, Yan W, You Y.

Oncotarget. 2015 Oct 6;6(30):30232-8. doi: 10.18632/oncotarget.4920.

9.

Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.

Fack F, Tardito S, Hochart G, Oudin A, Zheng L, Fritah S, Golebiewska A, Nazarov PV, Bernard A, Hau AC, Keunen O, Leenders W, Lund-Johansen M, Stauber J, Gottlieb E, Bjerkvig R, Niclou SP.

EMBO Mol Med. 2017 Dec;9(12):1681-1695. doi: 10.15252/emmm.201707729.

10.

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.

Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, Wiemels JL, Nelson HH, Karagas MR, Wrensch MR, Kelsey KT, Wiencke JK.

J Natl Cancer Inst. 2011 Jan 19;103(2):143-53. doi: 10.1093/jnci/djq497. Epub 2010 Dec 16.

11.

Molecular pathogenesis of IDH mutations in gliomas.

Ichimura K.

Brain Tumor Pathol. 2012 Jul;29(3):131-9. doi: 10.1007/s10014-012-0090-4. Epub 2012 Mar 8. Review.

PMID:
22399191
12.

cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.

Odia Y, Orr BA, Bell WR, Eberhart CG, Rodriguez FJ.

J Neurooncol. 2013 Nov;115(2):249-59. doi: 10.1007/s11060-013-1221-4. Epub 2013 Aug 11.

13.

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.

Oncotarget. 2015 Oct 6;6(30):30295-305. doi: 10.18632/oncotarget.4497.

14.

Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.

Reich TR, Switzeny OJ, Renovanz M, Sommer C, Kaina B, Christmann M, Tomicic MT.

Oncotarget. 2017 Feb 28;8(9):15071-15084. doi: 10.18632/oncotarget.14748.

15.

IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.

Qi ST, Yu L, Lu YT, Ou YH, Li ZY, Wu LX, Yao F.

Oncol Rep. 2011 Dec;26(6):1479-85. doi: 10.3892/or.2011.1428. Epub 2011 Aug 19.

PMID:
21874255
16.

IDH1 and IDH2 mutations in gliomas.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD.

N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710.

17.

[Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].

Liu QQ, Yin XX, Zou Y, Yu TP, Gong J, Chen XQ, Nie L, Xu M, Zhang MN, Zhou Q, Chen N.

Zhonghua Bing Li Xue Za Zhi. 2018 Sep 8;47(9):658-663. doi: 10.3760/cma.j.issn.0529-5807.2018.09.002. Chinese.

PMID:
30220117
18.

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.

Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W, Hu HM, Li MY, Wang HQ, He XZ, Zhu ZY, Liu YW, Zhang SZ.

J Exp Clin Cancer Res. 2016 May 31;35:86. doi: 10.1186/s13046-016-0362-7.

19.

TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK.

Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94. Epub 2014 Aug 1.

20.

Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.

Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, Cloughesy TF, Lai A.

Clin Cancer Res. 2014 Nov 15;20(22):5808-22. doi: 10.1158/1078-0432.CCR-14-0234. Epub 2014 Sep 15.

Supplemental Content

Support Center